SPY383.63+6.93 1.84%
DIA315.24+5.66 1.83%
IXIC12,920.15+196.68 1.55%

Regeneron Pharmaceuticals Q4 Adjusted Earnings Up As Revenue Grows 30%

· 02/05/2021 02:00

06:57 AM EST, 02/05/2021 (MT Newswires) -- Regeneron Pharmaceuticals (REGN) reported Friday Q4 adjusted earnings of $9.53 per diluted share, up from $7.50 a year ago. Analysts polled by Capital IQ expected $8.29.

Revenue for the quarter ended Dec. 31 totaled $2.42 billion, up 30% from $1.86 billion. Analysts polled by Capital IQ expected revenue of $2.40 billion.

The company said it expects U.S. regulatory action for Libtayo in both non-small cell lung cancer and basal cell carcinoma within the next month.

Price: 516.00, Change: +17.16, Percent Change: +3.44